All Things Biosimilar / Thought Leadership

A closer look at the first 100.

Public, source-backed perspectives on U.S. biosimilar approvals. Start with the retrospective, then test what you know about the products and their approval histories.

Explore the series

Two ways into the milestone

These public analyses are separate from the subscriber 351(k) Report, which covers ongoing market developments.

01 / Retrospective

The First 100 U.S. Biosimilar Approvals

From One to One Hundred: A Review of the First 100 U.S. Biosimilar Approvals

Follow the approval rhythm, compare specific reference-product markets, and explore elapsed time from first recorded BLA receipt to original approval. The analysis explains how ATB counts the milestone and links to its sources.

Explore the retrospective

02 / Interactive companion

The First 100 / Quiz

How well do you know the First 100?

Try a 10-question introduction or the optional 100-question challenge. Every question stays within the First 100 cohort, from reference products and approval dates to elapsed filing-to-approval days.

Take the quiz